EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis

Yusuke Yagi, Yuka Yamagishi, Yukihiro Hamada

Medical Mycology Journal · 2024

DOI: 10.3314/mmj.24.005 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Medical Mycology Journal, 2024. Verfasst von Yusuke Yagi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Kochi Medical School Hospital. Hauptthemen laut MEDLINE: Antifungal Agents, Pulmonary Aspergillosis, Triazoles. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic pulmonary aspergillosis (CPA) represents a spectrum of lung disorders caused by local proliferation of Aspergillus hyphae in individuals with non-systemic or mildly systemic immunodepression or altered pulmonary integrity due to underlying disease. While long-term systemic antifungal treatment is still the mainstay for management, surgery is considered mainly in rarer invasive disease manifestations such as sinusitis and osteomyelitis. Optimal application of existing antifungal agents with suitable pharmacokinetic properties is important for the treatment of diseases such as CPA, which requires long-term use. Appropriate management of side effects by therapeutic drug monitoring, maintenance of adherence, and assessment of drug resistance to Aspergillus can provide safe and effective treatment in the future. Most available antifungal agents for the management of mycoses in humans have disadvantages that can limit their use in clinical practice. By contrast, second generation antifungals such as triazoles have advantages of extended antifungal spectrum and availability in both oral and intravenous formulations. Isavuconazole, a new extended spectrum triazole, has been shown to be effective against Aspergillus. The safety profile and excellent pharmacokinetic characteristics of isavuconazole make it an attractive option for treatment of invasive fungal infections including CPA. With this drug now available in Japan, new evidence is expected to expand treatment options. This review focuses on the selection of antifungal agents based on national and international guidelines and the characteristics of each agent for their appropriate use in CPA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsPulmonary AspergillosisTriazolesHumansChronic DiseaseAspergillusPyridinesNitrilesDrug Resistance, Fungal

Stichwörter der Autor:innen

antifungal agentschronic pulmonary aspergillosisdrug resistance to Aspergillustherapeutic drug monitoring

Substanzen

Antifungal AgentsTriazolesisavuconazolePyridinesNitriles

Autor:innen und Institutionen

  • Department of Pharmacy, Kochi Medical School Hospital.
  • Department of Infection Prevention and Control, Kochi Medical School Hospital.
  • Department of Clinical Infectious Diseases, Kochi Medical School, Kochi University.

Zitieren

APA

Yagi, Y., Yamagishi, Y., & Hamada, Y. (2024). Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis. Medical Mycology Journal. https://doi.org/10.3314/mmj.24.005

Vancouver

Yagi Y, Yamagishi Y, Hamada Y. Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis. Medical Mycology Journal. 2024. doi:10.3314/mmj.24.005

BibTeX
@article{Yagi2024,
  author = {Yagi, Yusuke and Yamagishi, Yuka and Hamada, Yukihiro},
  title = {Optimized Antifungal Therapy for Chronic Pulmonary Aspergillosis},
  journal = {Medical Mycology Journal},
  year = {2024},
  doi = {10.3314/mmj.24.005}
}
Kostenlos starten →